Financial reports
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
24 Mar 22
Current reports
8-K
Regulation FD Disclosure
27 Mar 24
8-K
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8 Mar 24
8-K
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
16 Feb 24
8-K
Departure of Directors or Certain Officers
5 Dec 23
8-K
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
27 Nov 23
8-K
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
13 Nov 23
8-K
Ocuphire Corporate Presentation November 2023
2 Nov 23
8-K
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
1 Nov 23
8-K
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
27 Sep 23
8-K
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
11 Aug 23
Registration and prospectus
424B3
Prospectus supplement
16 Feb 24
S-8
Registration of securities for employees
11 Jan 24
S-3
Shelf registration
10 Jan 24
S-8
Registration of securities for employees
20 Nov 23
424B5
Prospectus supplement for primary offering
14 Aug 23
S-8
Registration of securities for employees
5 Apr 23
S-8
Registration of securities for employees
5 Apr 22
424B5
Prospectus supplement for primary offering
7 Jun 21
S-8
Registration of securities for employees
31 Mar 21
424B5
Prospectus supplement for primary offering
11 Mar 21
Proxies
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
10 Jun 22
DEFA14A
Additional proxy soliciting materials
2 Jun 22
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEF 14A
Definitive proxy
26 Apr 21
DEF 14A
Definitive proxy
29 Apr 19
DEFA14A
Additional proxy soliciting materials
11 Mar 19
DEF 14A
Definitive proxy
14 Feb 19
Other
EFFECT
Notice of effectiveness
24 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
19 Jan 24
UPLOAD
Letter from SEC
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
28 Jun 23
EFFECT
Notice of effectiveness
16 Feb 21
CORRESP
Correspondence with SEC
11 Feb 21
UPLOAD
Letter from SEC
10 Feb 21
EFFECT
Notice of effectiveness
5 Oct 20
Ownership